Plasma pharmacokinetics of ST-246, smallpox therapeutic, was evaluated in mice, rabbits, monkeys and dogs following repeat oral administrations by gavage. The dog showed the lowest Tmax of 0.83 h and the monkey, the highest value of 3.25 h. A 2- to 4-fold greater dose-normalized Cmax was observed for the dog compared to the other species. The mouse showed the highest dose-normalized AUC, which was 2-fold greater than that for the rabbit and monkey both of which by approximation, recorded the lowest value. The Cl/F increased across species from 0.05 L/h for mouse to 42.52 L/h for dog. The mouse showed the lowest VD/F of 0.41 L and the monkey, the highest VD/F of 392.95 L. The calculated extraction ratios were 0.104, 0.363, 0.231 and 0.591 for mouse, rabbit, monkey and dog, respectively. The dog showed the lowest terminal half-life of 3.10 h and the monkey, the highest value of 9.94 h. The simple allometric human VD/F and MLP-corrected Cl/F were 2311.51 L and 51.35 L/h, respectively, with calculated human extraction ratio of 0.153 and terminal half-life of 31.20 h. Overall, a species-specific difference was observed for Cl/F with this parameter increasing across species from mouse to dog. The human MLP-corrected Cl/F, terminal half-life, extraction ratios were in close proximity to the observed estimates. In addition, the first-in-humans (FIH) dose of 485 mg, determined from the MLP-corrected allometry Cl/F, was well within the dose range of 400 mg and 600 mg administered in healthy adult human volunteers.
Citation: Amantana A, Chen Y, Tyavanagimatt SR, Jones KF, Jordan R, Chinsangaram J, et al. (2013) Pharmacokinetics and Interspecies Allometric Scaling of ST-246, an Oral Antiviral Therapeutic for Treatment of Orthopoxvirus Infection. PLoS ONE 8(4): e61514. https://doi.org/10.1371/journal.pone.0061514
Editor: Anand S. Mehta, Drexel University College of Medicine, United States of America
Received: October 5, 2012; Accepted: March 8, 2013; Published: April 18, 2013
Copyright: © 2013 Amantana et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by Contract Title: NDA-Enabling Development for ST-246: A Smallpox Antiviral Drug; Contract Number: HHSN266200600014C; ADB Contract Number: N01-AI-60014. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have the following interests. Adams Amantana, Yali Chen, Shanthakumar R. Tyavanagimatt, Kevin F. Jones, Jarasvech Chinsangaram, Tove′ C. Bolken, Janet M. Leeds and Dennis E. Hruby are employed by SIGA Technologies, Inc. Robert Jordan was an employee of SIGA Technologies Inc., at the time of generating the data and drafting the initial version of this manuscript but has since joined Gilead Sciences, Foster City, CA. SIGA Technologies holds the patent on the drug being investigated in this study (ST-246). There are no further patents, products in development or marketed products to declare. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.
Variola virus (VAR), the etiological agent for smallpox has been eliminated by the successful global vaccination campaign coordinated by the World Health Organization (WHO). However, recent concerns over the potential to weaponize this virus and the possibility of accidental introduction into the environment of this and other poxviruses such as the monkeypox virus (MPX) have spurred profound interest in the development of small-molecule therapeutics for the prevention and treatment of smallpox. Also, the absence of an active vaccination campaign, coupled with potential health risks associated with the existing vaccine regimen all render highly imperative, the development of a safe and effective antiviral therapeutic for use as a countermeasure against poxvirus infection.
ST-246 with molecular structure as shown in Figure 1, is an orally bioavailable molecule that is being developed by SIGA Technologies, for treatment of orthopoxvirus infections including smallpox. This compound has been shown to be extremely effective against a variety of orthopoxviruses, both in vitro and in multiple animal species –.
Safety studies conducted in rodents, non-rodents and non-human primates at dose levels several fold greater than the efficacious dose indicate a high therapeutic index .
This current study describes the oral plasma pharmacokinetics and utilizes traditional allometry to explore the interspecies relationship of the pharmacokinetics of ST-246 following oral single and repeat dose administrations. Preclinical data not only supports the assessment of drug safety, but is also useful in the determination of human pharmacokinetics for the selection of a dose for first-in-human trials. The ability to make such determinations is vital in optimizing the dose selection processes by minimizing time and cost in drug development , .
Mainly, two approaches, the physiologically-based model and allometric scaling are routinely utilized for interspecies pharmacokinetic scaling but with varying predictive success. Although the physiological model is mechanistic in nature and has been applied in the evaluation and extrapolation of drug pharmacokinetics –, this approach is limited on the basis of cost, mathematical complexity, prolonged processing time and a high failure rate . It is in view of these limitations that scaling by allometry, has gained broad application for interspecies pharmacokinetic extrapolation  and has been successfully applied to several small molecules. In this technique, preclinical pharmacokinetic parameters, plasma clearance (Cl/F) and apparent volume of distribution (VD/F) are scaled by the exponential function of body weight (BW) –. The predictive performance for this technique depends on factors such as data quality, number and type of species utilized in the extrapolation as well as the proper identification of the combination of physiological parameters and scaling factors that best relate to the disposition of a given molecule. Although, adequate extrapolations for Cl/F have been achieved based on the relation Y = AWB, this is not always the case as this model has the tendency to over-predict this parameter in some instances. In this regard, modified allometric scaling methods involving correction for animal brain weight  and maximum life span potential (MLP) ,  are being utilized to improve prediction. The application of either one of these correction factors is determined by the “Rule of Exponents” (RoE) , . The ROE states the following: A) if the exponent from the simple allometric equation is less than 0.50 or occurs between 0.55 and 0.70, then simple allometry is applied; B) if the simple allometry exponent is between 0.70 and 1.0, then the Cl/F X MLP correction approach is applied and C) if the simple allometry exponent is greater than 1.0, then the Cl/F X BrW correction approach is applied. MLP is calculated according to the following equation, MLP = 185.4 X (BrW) 0.636 X (BW)−0.225 .
Since oral administration is the preferred route for most drugs in clinical settings, the application of allometry for extrapolation to human pharmacokinetics will inevitably require the use of preclinical oral pharmacokinetics. Physiological factors, especially those associated with the gastrointestinal tract such as pH, blood flow rate and gastrointestinal transit time as well as the level of expression of enzyme systems involved in first-pass metabolism can determine the oral pharmacokinetic profiles for various molecules which in turn determine the outcome of interspecies scaling. Since these factors vary from species to species, preclinical species combination for scaling is crucial to the predictive success of this scaling technique.
In this study, we describe the oral plasma pharmacokinetics of ST-246 in animal species namely, BALB/c mice, New Zealand White Hra:(NZW)SPF albino rabbits, cynomolgus monkeys and beagle dogs as well as determine human oral plasma clearance (Cl/F), apparent volume of distribution (VD/F) and terminal half-life (t1/2) by interspecies allometric scaling.
Materials and Experimental Procedures
ST-246 (Tecovirimat: 4-trifluoromethyl-N-(3,3a,4,4a,5,5a,6,6aoctahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2(1H)-yl)-benzamide) was synthesized by Pharmacore, High Point, North Carolina, USA and the identity confirmed by IR, MS, elemental analysis and NMR. Purity by HPLC was determined to be at least 95%. Other chemicals purchased from standard vendors include were of the highest purity possible.
Animals for Pharmacokinetic Evaluation
Approximately six- to 10-week old BALB/c mice were received from Charles River Laboratories, Raleigh, North Carolina, USA and five- to six-months old New Zealand White Hra:(NZW)SPF albino rabbits were purchased from Covance Research Products, Inc., Kalamazoo, Michigan, USA.
Two- to three-year old cynomolgus monkeys were purchased from Covance Research Products, Alice, Texas, USA. Six- to eight-year beagle dogs were purchased from Marshall BioResources, U.S.A., Inc. North Rose, New York, USA.
All animals were housed in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals in individual cages placed in rooms fitted with unidirectional airflow systems, with temperature ranging from 64 to79°F, 61 to72°F, 64–84°F and 66–80°F for mice, rabbits, monkeys and dogs, respectively, and relative humidity ranging from 30 to 70% with a 12-hour light/dark cycle (6∶00 AM–6∶00 PM). Filtered tap water was available ad libitum via an automatic water system. The mice, rabbits, monkeys and dogs were fed a standard animal diet from PMI Nutritional International Inc., Saint Paul, Minnesota, USA, namely, Lab Diet® Certified Rodent Diet #5002, Lab Diet® Certified Rabbit Diet #5332 and Lab Diet® Certified Primate Diet #5048 and Lab Diet® Certified Canine #5007, respectively, and was available to the animals ad libitum. Food and water were withdrawn at periods during which dosing of the test article or blood draws for pharmacokinetic evaluation were conducted.
Preclinical Pharmacokinetic Evaluation
The studies involving the mice, rabbits and monkeys were conducted at the MPI Research testing facility, Mattawan, MI, USA while that involving the dogs was conducted at Huntingdon Life Sciences, East Millstone, NJ, USA., in accordance with all Federal, State and Local guidelines for laboratory animal care and use. The use of these animals followed study protocols that were carefully reviewed and approved by the facility’s Institutional Animal Care and Use Committee (IACUC) as well as the IACUC for SIGA Technologies prior to the start of each study. In addition, all studies were conducted in compliance with the testing facility’s Animal Welfare Assurance (OLAW Assurance number A3181-01) filed with the National Institutes of Health. Veterinary care (vivarium rounds) by an American College of Laboratory Animal Medicine (ACLAM)-certified clinical veterinarian was available at all times throughout these studies at these facilities. In-life staff (technical operations and animal care) performed daily (AM and PM) husbandry procedures. Health monitoring, prophylactic and therapeutic treatments were conducted under the direction of a qualified veterinarian at these facilities. The veterinary staff monitored all animals and in the event where any of the animals exhibited any clinical signs, the appropriate treatment and supportive care were administered. Based on veterinary recommendation, animals experiencing severe or chronic pain/distress that could not be relieved were humanely euthanized without delay. Also, animals that made it to study termination were also humanely euthanized. The following methods of euthanasia that comply with the AVMA Guidelines on euthanasia were utilized. The mice were euthanized by anesthesia by carbon dioxide/oxygen inhalation followed by exsanguination. The rabbits were euthanasia by sodium pentobarbital administration followed by exsanguination. The monkeys were euthanized by ketamine sedation and by sodium pentobarbital administration followed by exsanguination. The dogs were euthanasia was by an intravenous overdose of sodium pentobarbital solution followed by exsanguination.
ST-246 was administered perorally by gavage as a suspension consisting of 1% hydroxypropyl methylcellulose (HPMC) in deionized water/0.5% Tween 80® for the plasma pharmacokinetic evaluation of this molecule. Verification of homogeneity stability and concentration of ST-246 the dose formulations was performed by HPLC with a UV system. Plasma concentration-time course data for non-compartmental pharmacokinetic evaluation in each of the species tested was generated based on the following study designs:
Pharmacokinetics in mice.
Male and female BALB/c mice were given single daily administrations of ST-246 at dose of 2000 mg/kg, a dose volume of 10 mL/kg body weight for 28 consecutive days. Whole blood samples will be collected from the orbital sinus after carbon dioxide/oxygen inhalation at 1, 2, 3, 4, 6, 8, 10, 12 and 24 h following administration.
Pharmacokinetics in rabbits.
In a seven-day repeat dose study, male and female New Zealand White Hra: (NZW) SPF albino rabbits received peroral single daily doses of ST-246 by gavage, at 100 mg/kg, at a dose volume of 10 mL/kg body weight. Plasma concentration of ST-246 was determined from whole blood samples collected via the ear vein at 0, 0.5, 1, 2, 3, 4, 5, 6, 8, 12 and 24 h post-dose administration.
Pharmacokinetics in monkeys.
Male and female cynomolgus monkeys received ST-246 as single daily peroral administrations by gavage at100, at a dose volume of 10 mL/kg for 28 days. For the determination of plasma concentration of ST-246, whole blood samples were drawn via the femoral vein at 0, 1, 2, 3, 4, 5, 6, 8, 12 and 24 h following administration.
Pharmacokinetics in dogs.
Male and female beagle dogs received ST-246 as single daily peroral administrations by gavage at dose of 30 mg/kg, at a dose volume of 10 mL/kg body weight for 7 consecutive days. Blood samples were drawn via the jugular vein at 0.5, 1, 2, 3, 4, 6, 8, 10, 12 and 24 h following administration.
Whole blood samples collected in all of these studies at the specified time points were immediately placed in tubes containing sodium heparin anticoagulant, stored on ice blocks until processed. The plasma generated from the blood samples were placed in clean tightly capped, pre-labeled plastic vials and frozen at approximately −70°C to await bioanalysis.
Bioanalytical Reagents and Procedure
Quantitative analysis of the plasma samples at each time point was performed by liquid chromatography-tandem mass spectrometry (LC-MS/MS) (HPLC system: Agilent 1100 Series quaternary pump with on-line degasser, thermostatted well-plate autosampler and column compartment). Extraction of ST-246 from each sample was conducted by simple methanol (MeOH) protein precipitation in the presence of an isotopic internal standard for the preclinical samples. Briefly, 50 µL of uniformly mixed plasma was transferred into each well in a 96-well plate containing 5 µL working standard solution for calibration standards or working QC solution followed by the addition of a 150 µL of precipitation solution, MeOH containing the internal standard, 13C4-ST-246 (KXN-2327). This mixture was subsequently centrifuged at 4000 rpm for 5 minutes and a 100 µL aliquot was then added to the corresponding well in a fresh 96-well plate already containing 200 µL aliquot of the water/MeOH (50∶50 v/v) diluent. In the case of the clinical samples, solid phase extraction on an ISOLUTE®-96 Fixed Well Plate 200 mg SLE+ plate was performed. Briefly, 50.0 µL of each standard, sample, or blank was added to a v-bottom 96-well extraction plate. Then 50.0 µL of the working internal standard (WIS) was added to all wells except the double blanks. In place of WIS, 50.0 µL of Methanol/Water (50∶50 v/v) was placed in the double blanks wells. 100 µL of analytical grade water was then added to the appropriate wells of the 96-well plate. This was then thoroughly mixed and transferred to an ISOLUTE SLE®+ plate. Samples were then loaded onto the ISOLUTE SLE®+ plate with little or no vacuum and allowed to sit for approximately 5 minutes. The waste receptacle was replaced with the 96-well collection plate and 500 µL of methyl tertiary butyl ether (MTBE) added to all wells and eluted with minimal vacuum. An additional 500 µL of MTBE was added to all wells and eluted with minimal vacuum. The organic layer was evaporated under nitrogen at approximately 50°C. After the plate was dried, all samples were reconstituted with 500 µL of 0.05% NH4OH and 0.05% Acetic acid in MeOH/H2O (65∶35 v/v) and mixed. 50.0 µL of the reconstituted samples were subsequently diluted with 450 µL 0.05% NH4OH and 0.05% Acetic Acid in MeOH/H2O (65∶35 v/v) and thoroughly mixed.
Chromatographic separation was performed by means of a Phenomenex LUNA C18, 30×2 mm, 5 µm particle size column in 10 mM ammonium acetate (NH4AcO)/0.05% ammonium hydroxide (NH4OH) buffer in acetonitrile (ACN)/MeOH (50∶50 v/v) at a flow rate of 300 µL/min for the mobile phase. Analysis was conducted on Applied Biosystems/MDS SCIEX API 3000/4000 tandem liquid chromatography mass spectrometry (LC/MS/MS) using turbospray ionization in the negative ion mode. The mass spectrometer was tuned to the multiple reaction monitoring (MRM) scan mode to follow the m/z transitions, 375.1-282.9 and 340.9-248.9 for ST-246 and the internal standard, respectively. The linear calibration curve was calculated by the “least squares” method with a weighting factor of 1/X2 over the concentration range of 5.00–2000 ng/mL. The accuracy and precision of the bioanalytical method were within the acceptable criteria limits of ±15% RE of the nominal at all other concentrations and ±20% RE of the nominal for the LLOQ (5.00 ng/mL) .
Plasma Concentration Data Processing
WinNonLin Professional Edition, Version 4.0 (Pharsight Corporation, Mountain View, CA, USA) was used to determine pharmacokinetic parameter estimates from the plasma ST-246 concentration data. The plasma exposure or area under the plasma concentration versus time curve (AUC) up to the time of the last quantifiable sample was calculated using the linear trapezoidal rule and was extrapolated to time infinity by the equation AUCt+(Clast/kel), where Clast is the concentration at the last quantifiable sampling time and kel is the elimination rate constant, determined by linear regression of the terminal log-linear phase of the concentration-time curve. Plasma clearance confounded by absolute oral bioavailability (Cl/F) was estimated based on the equation, Cl/F = Dose/AUC. The apparent volume of distribution confounded by absolute oral bioavailability (VD/F) was estimated as VD/F = Dose/(AUC×kel), where kel is the elimination rate constant. The terminal half-life (t1/2) was estimated by the relation t1/2 = In2/kel. The time (Tmax) to reach peak plasma concentration (Cmax) was determined directly from the observed plasma concentration versus time profiles. The calculated extraction ratio values were determined by the relation, Extraction ratio = Cl/F/Cardiac Output.
Allometric scaling across species was performed to predict human plasma clearance (Cl/F) and apparent volume of distribution (VD/F). For our scaling process, simple allometry relating a given pharmacokinetic parameter to animal body weight (BW) was considered.
Each pharmacokinetic parameter, based on the simple allometric approach, was plotted against the body weight on a log-log scale based on the following power-based simple allometric equations for:
α&β = the allometric coefficients; A and B = Allometric Exponents.
BW = Body Weight; BrW = Brain Weight;
MLP = Maximum Life Span Potential.
Extrapolation to human pharmacokinetic parameters was based on a 70 kg body weight , . In this evaluation, the Cl/F and VD/F were plotted against animal body weight on a log-log scale . Linear regression analysis was then performed using GraphPad Prism 5.0, GraphPad Software, Inc. La Jolla, CA, USA, according to the logarithmic transformations of the simple allometric equations as shown below for:
First-in-Humans Dose Determination from Allometrically Scaled Human Clearance
A slight modification , of the pharmacologically guided approach, provided in the United State Food and Drug Administration (USDFA) draft guidance , was used to determine the first-in-humans (FIH) dose for ST-246 from the scaled human plasma clearance (Cl/F) value. In this approach , no safety factor was applied based on the assumption that the administered animal dose was significantly lower than a NOAEL, hence, the FIH dose expressed is as shown in the equation below:Where AUC is the lowest observed systemic exposure value among the species utilized in this study.
The plasma concentration of ST-246 in mice, rabbits, monkeys and dogs following repeat oral administration are presented as plasma concentration versus time profiles and illustrated in Figures 2, 3, 4, and 5 and the pharmacokinetic estimates (mean ±SD) are presented in Tables 1 and 2.
The adjacent plot represents the corresponding semi-logarithmic plot.
The adjacent plot represents the corresponding semi-logarithmic plot.
The adjacent plot represents the corresponding semi-logarithmic plot.
The adjacent plot represents the corresponding semi-logarithmic plot.
As shown in Table 1, the lowest mean time to reach peak plasma concentration (Tmax) of 0.83 h was observed for the dog and the highest value of 3.25 h for the monkey. Also, a 2- to 4-fold greater dose-normalized peak plasma concentration (Cmax) was observed for the dog compared to the other species as listed in Table 2. The mouse showed the highest dose-normalized AUC, which was 2-fold greater than that for the rabbit and monkey both of which, by approximation showed the lowest dose-normalized AUC value, as shown in Table 2. The mean estimated plasma clearance (Cl/F) increased across species, from 0.05 L/h for mouse to 42.52 L/h for dog as displayed in Table 1. Also, as listed in Table 1, the dog showed the lowest mean terminal half-life of 3.10 h and the monkey, the highest value of 9.94 h. The lowest mean VD/F of 0.41 L was observed for the mouse and for the monkey, the highest estimate of 392.95 L as presented in Table 1. As listed in Table 2, the estimated extraction ratios for these animal species were 0.104, 0.363, 0.231 and 0.591 for mouse, rabbit, monkey and dog, respectively.
Table 3 shows the allometric coefficient, exponent, and the coefficient of determination values derived from linear regression analysis of the of the log-transformed animal Cl/F or VD/F versus the corresponding log-transformed animal body weight as presented in Figures 6 and 7 for Cl/F and Figure 8 for VD/F. As presented in Table 3, the regression analysis showed strong correlation based on the coefficients of determination (R-squared values) for the Cl/F, (0.9843 and 0.9107 for simple and maximum life span potential (MLP)-corrected allometry, respectively) and for VD/F, (0.9294 for simple allometry). Also, as presented in Table 3, the allometric exponent derived from simple allometric analysis was 1.0092 for Cl/F and 1.0678 for VD/F and that derived from MLP-corrected allometry for Cl/F was 1.2788. Table 4 shows the observed human pharmacokinetic estimates at dose levels of 400, 600 and 800 mg and scaled Cl/F estimates of 254.02 L/h and 51.35 L/h by simple and MLP-corrected allometry, respectively, and scaled VD/F estimate of 2311.5 L by simple allometry. Also, as shown in Table 4, human terminal half-life values of 6.31 h (using the simple allometry Cl/F and VD/F estimates) and 31.20 h (using the simple allometry VD/F and the MLP-corrected allometry Cl/F estimates) were determined according to the relation t1/2 = In2*(VD/F)scaled/(Cl/F)scaled.
In addition, Table 4 shows the human extraction ratio values of 0.111, 0.143 and 0.109 calculated from the observed Cl/F at the 400, 600 and 800 mg dose levels, respectively, 0.153 determined from the MLP-corrected allometry Cl/F and 0.756 determined from the simple allometry Cl/F estimates. Also, the human extraction ratio calculated from the MLP-corrected allometry Cl/F and presented in Table 4, was more proximal to the observed human values of (at all of the different administered dose levels) compared to that determined from the simple allometry Cl/F. In addition, the first-in-humans (FIH) dose of 485 mg, calculated from the MLP-corrected allometry Cl/F estimate, showed reasonable proximity to the given low and median dose levels of 400 and 600 mg, respectively, as listed in Table 4.
Plasma pharmacokinetics of the anti-orthopoxvirus agent, ST-246, was evaluated following repeat-dose oral administrations by gavage, to four different animal species, namely, BALB/c mice, New Zealand White Hra:(NZW)SPF albino rabbits, cynomolgus monkeys and beagle dogs. The animal plasma clearance (Cl/F) estimate was scaled by simple and MLP-corrected allometry and the apparent volume of distribution (VD/F) estimate scaled by simple allometry, in order to determine human Cl/F and VD/F.
The lowest mean time to reach peak plasma concentration (Tmax) value of 0.83 h was observed for the dog and the highest value of 3.25 h for the monkey. Also, the dog showed a 2- to 4-fold greater dose-normalized peak plasma concentration (Cmax) compared to the other species. The highest dose-normalized area under the curve (AUC) was observed for the mouse, which was 2-fold greater than that for the rabbit and monkey both of which, by approximation, showed the lowest dose-normalized AUC. This observed species-specific difference in the dose-normalized Cmax and AUC could be due to differences in gastrointestinal transit time and/or first-pass effect. The estimated Cl/F was observed to increase across species, from 0.05 L/h for mouse to 42.52 L/h for dog. Except for the dog, the terminal half-life estimates showed a modest increase from mouse to monkey despite the significant increase in the corresponding Cl/F estimates across these species. This observation is due to the fact that the terminal half-life is a hybrid parameter, which is also influenced by VD/F and as can be seen in Table 1, the VD/F increased significantly from mouse to monkey.
The low terminal half-life observed for the dog is consistent with the very high Cl/F and low VD/F estimates for this species, as presented in Table 1. In addition, the dog showed a relatively high extraction ratio as listed in Table 2, indicating that this species has approximately a 6-, 2-, and 3-fold greater ability to clear ST-246, compared to the mouse, rabbit and dog, respectively.
Interspecies allometric scaling is one approach used for scaling preclinical pharmacokinetics in order to predict human pharmacokinetics necessary for dose selection in first-in-human (FIH) studies. Mahmood and Balian have reported that three or more preclinical species is adequate for reliable scaling of Cl/F by allometry . In this current study, the Cl/F and VD/F estimates from four species namely, mouse, rabbit, monkey and dog, were scaled to determine human Cl/F and VD/F, which were then used to calculate human terminal half-life and extraction ratio estimates. It has been reported that the allometric exponent, depending on the combination of species used in the scaling process, could range anywhere from 0 to 1 and sometimes even higher , . The simple allometric exponent for Cl/F, as shown in Table 3, was slightly higher than the generally accepted baseline physiological range of 0.6 to 0.8 while that for VD/F was very consistent with the accepted range of 0.8 to 1.0. Based on the “Rule of Exponents” (RoE) , , the Cl/F multiplied by the maximum life span (MLP) correction approach was applied in this study to improve the human Cl/F determination, since the allometric exponent derived from the simple allometry plot was 1.0092, which approximates to 1.0.
The equation, t1/2 = In2*(VD/Fscaled)/(Cl/Fscaled) has been utilized to indirectly determine human terminal half-life from the allometrically scaled human Cl/F and VD/F estimates , , . As shown in Table 3, the simple and MLP-corrected allometry produced a terminal half-life of 6.31 h and 31.22 h, respectively.
Generally, for FIH studies, the Cl/F estimate is the parameter of most interest in dose selection. To establish good safety margin in a FIH study, a relatively lower Cl/F is required to determine a safe dose. Hence, the MLP-corrected allometry-derived human Cl/F of 51.35 L/h (with a corresponding extraction ratio of 0.153 and a terminal half-life of 31.20 h) showed greater proximity to the observed human estimates at the different administered dose levels (as shown in Table 4) compared to the simple allometry-derived Cl/F of 254.0L/h (with a corresponding extraction ratio of 0.756 and a terminal half-life of 6.31 h) and therefore was utilized in the determination of a recommended starting dose in humans.
Also, since terminal half-life is directly related to VD/F, it goes to suggest that the large allometrically determined human VD/F (which is approximately 6-fold higher than the highest VD/F estimate, which was observed for the monkey) in this evaluation, should produce a relatively longer terminal half-life. Hence, the terminal half-life of 31.20 h calculated from the MLP-corrected allometry Cl/F appeared more reasonable and in fact, showed greater proximity to the observed human estimates than the value of 6.31 h determined from the simple allometry Cl/F, as presented in Table 4. In addition, the closeness of the MLP-corrected allometry Cl/F to the observed human estimates is supported by the closeness of the human extraction ratio (calculated from the MLP-corrected allometry Cl/F) to those determined from the observed Cl/F at the different dose levels administered in the adult human volunteers.
Interspecies scaling by allometry has enjoyed broader application in the prediction of human pharmacokinetics from animal data and is becoming an attractive and useful strategy in the determination of FIH dose . In this evaluation, the calculated FIH dose of 485 mg from the MLP-corrected allometry Cl/F and the lowest animal AUC was in reasonable agreement with the low and median dose levels of 400 mg and 600 mg, respectively, administered in healthy adult human volunteers as shown in Table 4.
In summary, this evaluation shows a species-specific difference in the Cl/F for ST-246 following repeat oral administration and observed to increase across the animal species from mouse to dog. The overall shallow increase in terminal half-life across species, despite the corresponding increase in Cl/F from mouse to human can be accounted for by the significant increase in VD/F across these species.
Finally, the human MLP-corrected allometry CL/F, terminal half-life (calculated from the MLP-corrected allometry Cl/F and the simple allometry VD/F values) as well as the recommended FIH dose (determined from the MLP-corrected allometry Cl/F) are in close proximity to the corresponding observed values presented herein for healthy adult human volunteers. Hence, this current evaluation shows that not only is interspecies scaling of animal pharmacokinetics useful in the prediction of human pharmacokinetics, it is also valuable in dose selection for FIH trials.
The authors wish to thank all the staff members of MPI Research, Mattawan, MI who partnered with the Authors of this manuscript in the design, conduct and reporting of the findings of these studies.
Conceived and designed the experiments: AA YC SRT KFJ RJ JC TCB JML DEH. Analyzed the data: AA YC SRT JML. Wrote the paper: AA YC SRT KFJ RJ JC TCB JML DEH.
- 1. Duraffour S, Snoeck R, de Vos R, van Den Oord JJ, Crance J-M, et al. (2007) Activity of the anti-orthopoxvirus compound ST-246 against vaccinia, cowpox and camelpox viruses in cell monolayers and organotypic raft cultures. Antiviral Ther 12: 1205–1216.
- 2. Quenelle DC, Buller RM, Parker S, Keith KA, Hruby DE, et al. (2007) Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. Antimicrob Agents and Chemother 51: 689–695.
- 3. Sbrana E, Jordan R, Hruby DE, Mateo RI, Xiao SY, et al. (2007) Efficacy of the antipoxvirus compound ST-246 for treatment of severe orthopoxvirus infection. Am J Tropical Med and Hyg 76: 768–773.
- 4. Nalca A, Hatkin JM, Garza NL, Nichols DK, Norris SW, et al. (2008) Evaluation of orally delivered ST-246 as postexposure prophylactic and antiviral therapeutic in an aerosolized rabbitpox rabbit model. Antiviral Res 79: 121–127.
- 5. Huggins J, Goff A, Hensley L, Mucker E, Shamblin J, et al. (2009) Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. Antimicrob Agents and Chemother 53: 2620–2625.
- 6. Jordan R, Goff A, Frimm A, Corrado ML, Hensley LE, et al. (2009) ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification. Antimicrob Agents and Chemother 53: 1817–1822.
- 7. Yang G, Pevear DC, Davies MH, Collett MS, Bailey T, et al. (2005) An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus challenge. J of Virol 79: 13139–13149.
- 8. Chen Y, Honeychurch KM, Yang G, Byrd CM, Harver C, et al. (2009) Vaccinia virus p37 interacts with host proteins associated with LE-derived transport vesicle biogenesis. Virol J 6: 1–12.
- 9. DiMasi JA (1994) Risks, regulation, and rewards in new drug development in the United States. RegulToxicol Pharmacol 19: 228–235.
- 10. Kuhlmann J (1997) Drug research: from the idea to the product. Int J Clin.Pharmacol Ther 35: 541–552.
- 11. Bischoff KB (1975) Some fundamental considerations of the applications of pharmacokinetics to cancer chemotherapy. Cancer Chemother Rep 59: 777–793.
- 12. Sugita O, Sawada Y, Sugiyama Y, Iga T, Hanano M (1982) Physiologically based pharmacokinetics of drug-drug interaction: a study of tolbutamide-sulfonamide interaction in rats. J Pharmacokinet Biopharm 10: 297–316.
- 13. Lin JH, Sugiyama Y, Awazu S, Hanano M (1982) Physiological pharmacokinetics of ethoxybenzamide based on biochemical data obtained in vitro as well as on physiological data. J Pharmacokinet Biopharm 10: 649–661.
- 14. King FG, Dedrick RL, Farris FF (1986) Physiological pharmacokinetic modeling of cis-dichlorodiammineplatinum(II) (DDP) in several species. J. Pharmacokinet Biopharm 14: 131–155.
- 15. Ings RM (1990) Interspecies scaling and comparisons in drug development and toxicokinetics. Xenobiotica 20: 1201–1231.
- 16. Ritschel WA, Vachharajani NN, Johnson RD, Hussain AS (1992) The allometric approach for interspecies scaling of pharmacokinetic parameters. Comp Biochem Physiol C 103: 249–253.
- 17. Boxenbaum H (1982) Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics. J Pharmacokinet Biopharm 10: 201–227.
- 18. Mahmood I, Balian JD (1999) The pharmacokinetic principles behind scaling from preclinical results to phase I protocols. Clin Pharmacokinet 36: 1–11.
- 19. Lave T, Coassolo P, Reigner B (1999) Prediction of hepatic metabolic clearance based on interspecies allometric scaling techniques and in vitro-in vivo correlations. Clin Pharmacokinet 36: 211–231.
- 20. Mahmood I, Balian JD (1996b) Interspecies scaling: predicting clearance of drugs in humans. Three different approaches. Xenobiotica 26: 887–895.
- 21. Boxenbaum H (1980) Interspecies variation in liver weight, hepatic blood flow, and antipyrine intrinsic clearance: extrapolation of data to benzodiazepines and phenytoin. J Pharmacokinet Biopharm 8: 165–176.
- 22. Mahmood I, Balian JD (1996c) Interspecies scaling: predicting pharmacokinetic parameters of antiepileptic drugs in humans from animals with special emphasis on clearance. J Pharm Sci 85: 411–414.
- 23. Sacher GA (1959) Relation of life span to brain weight and body weight in mammals. In: Wolstenholme GEW, O’Connor M, editors. The Lifespan of Animals. London: Little, Brown and Company. pp. 115–133.
- 24. Guidance for Industry, Bioanalytical Method Validation, U.S. Department of Health and Human Services, Food and Drug Administration, May 2001.
- 25. Davies B, Morris T (1993) Physiological parameters in laboratory animals and humans. Pharm.Res 10: 1093–1095.
- 26. Mahmood I, Green MD, Fisher JE (2003) Selection of the first-time dose in humans: comparison of different approaches based on interspecies scaling of clearance. J Clin Pharmacol 43: 692–697.
- 27. U.S. Food and Drug Administration: Guidance for industry: estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. Fed Reg 2005: 1–27.
- 28. Mahmood I, Balian JD (1996a) Interspecies scaling: a comparative study for the prediction of clearance and volume using two or more than two species. Life Sci 59: 579–585.
- 29. Mahmood I (2005) Interspecies scaling of clearance. In: Mahmood, I, editor. Interspecies Pharmacokinetic Scaling: Principles and Application of Allometric Scaling. Rockville, MD. Pine House Publishers. pp. 39–85.
- 30. Hu TM, Hayton WL (2001) Allometric scaling of xenobiotic clearance: uncertainty versus universality. AAPS PharmSci 3: 30–43.
- 31. Bachmann K (1989) Predicting toxicokinetic parameters in humans from toxicokinetic data acquired from three small mammalian species. J Appl Toxicol 9: 331–338.
- 32. Obach RS, Baxter JG, Liston TE, Silber BM, Jones BC, et al. (1997) The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther 283: 46–58.
- 33. Boxenbaum H, DiLea C (1995) First time in human dose selection: allometric thoughts and perspectives. J Clin Pharmacol 35: 957–966.